Bo Tang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Tang has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Huihui Liu
Department of Hematology, Peking University First Hospital
1 shared publicationJialin Zhu
Department of Hematology, Peking University First Hospital
1 shared publicationMingyi Di
Department of Hematology, Peking University First Hospital
1 shared publicationWei Liu
Department of Hematology, Peking University First Hospital
1 shared publicationWenmin Tian
Center for Precision Medicine Multi-Omics Research, Institute of Advanced Clinical Medicine, Peking University
1 shared publication- Xiaodi Yang
Department of Hematology, Peking University First Hospital, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 4 August 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0399625
Proteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection
Patients with hematologic malignancies (HMs) are particularly vulnerable to coronavirus disease 2019 (COVID-19) because of underlying immune dysfunction and treatment-related immunosuppression. However, proteomic features associated with different clinical trajectories in this population remain insufficiently characterized. We performed serum proteomic analysis in 40 HM patients with COVID-19 and 15 healthy controls. Compared with controls, HM patients showed impaired immune-related responses during the acute phase of COVID-19. Acute-phase proteomic patterns differed across outcome groups; however, because outcome groups were closely intertwined with initial COVID-19 severity, ICU admission, and systemic illness, and because multivariable adjustment was not performed due to the limited sample size, these patterns should be interpreted as severity- and outcome-associated profiles rather than independent trajectory-specific markers. Fatal cases showed evidence of dysregulated immune activation, whereas patients later classified as having long COVID exhibited broader suppression of immune-related pathways. In addition to immune alterations, pathways related to platelet activation and cardiac-related dysfunction were associated with adverse clinical trajectories. Enzyme-linked immunosorbent assay validation supported the association of selected proteins with outcome groups during acute infection. These findings provide a proteomic overview of COVID-19 in HM patients and offer a basis for future mechanistic studies and larger external validation cohorts. IMPORTANCE: Patients with hematologic malignancies are highly vulnerable to severe coronavirus disease 2019 (COVID-19), acute death, and long COVID due to preexisting immune dysfunction. However, the proteomic signatures linked to adverse clinical trajectories remain poorly understood. Our serum proteomic study identifies distinct acute-phase immune profiles associated with different outcomes: broad immune suppression characterizes long COVID, while dysregulated immune activation is associated with fatal cases. Platelet activation and cardiac-related pathways are also linked to poor outcomes. These findings provide key molecular insights for this high-risk population, supporting future biomarker development, risk stratification, and targeted clinical management. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT05683353 .
- 4 August 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (8) , e0399625
Open AccessProteomic analysis identifies pathways related to immune dysregulation in patients with hematologic malignancies after COVID-19 infection
Patients with hematologic malignancies (HMs) are particularly vulnerable to coronavirus disease 2019 (COVID-19) because of underlying immune dysfunction and treatment-related immunosuppression. However, proteomic features associated with different clinical trajectories in this population remain insufficiently characterized. We performed serum proteomic analysis in 40 HM patients with COVID-19 and 15 healthy controls. Compared with controls, HM patients showed impaired immune-related responses during the acute phase of COVID-19. Acute-phase proteomic patterns differed across outcome groups; however, because outcome groups were closely intertwined with initial COVID-19 severity, ICU admission, and systemic illness, and because multivariable adjustment was not performed due to the limited sample size, these patterns should be interpreted as severity- and outcome-associated profiles rather than independent trajectory-specific markers. Fatal cases showed evidence of dysregulated immune activation, whereas patients later classified as having long COVID exhibited broader suppression of immune-related pathways. In addition to immune alterations, pathways related to platelet activation and cardiac-related dysfunction were associated with adverse clinical trajectories. Enzyme-linked immunosorbent assay validation supported the association of selected proteins with outcome groups during acute infection. These findings provide a proteomic overview of COVID-19 in HM patients and offer a basis for future mechanistic studies and larger external validation cohorts. IMPORTANCE: Patients with hematologic malignancies are highly vulnerable to severe coronavirus disease 2019 (COVID-19), acute death, and long COVID due to preexisting immune dysfunction. However, the proteomic signatures linked to adverse clinical trajectories remain poorly understood. Our serum proteomic study identifies distinct acute-phase immune profiles associated with different outcomes: broad immune suppression characterizes long COVID, while dysregulated immune activation is associated with fatal cases. Platelet activation and cardiac-related pathways are also linked to poor outcomes. These findings provide key molecular insights for this high-risk population, supporting future biomarker development, risk stratification, and targeted clinical management. CLINICAL TRIALS: This study is registered with ClinicalTrials.gov as NCT05683353 .